{"entity":{"id":"nct06640166","kind":"trial","name":"Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafen","aka":["ECLYPse"],"tldr":"A phase 2 trial in colorectal cancer, run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS, now recruiting.","summary":"Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. is a phase 2, interventional study registered as NCT06640166 by Fondazione Policlinico Universitario Agostino Gemelli IRCCS, with a registry enrolment figure of 25 participants, started 2024-06-03 and due to reach its primary completion in 2025-12-31. Interventions recorded: encorafenib + cetuximab + FOLFIRI. Conditions listed: Colorectal Carcinoma; Colorectal Neoplasms; Colorectal Tumor; Colorectal Adenocarcinoma; Colorectal Cancer (CRC); Colorectal Cancer; Colon Cancer; Colon Adenocarcinoma; Colon Carcinoma; Colon Neoplasm. Primary outcome: 6-month Progression Free Survival rate. Colorectal eligibility wording from the registry: \"* histologically or cytologically confirmed diagnosis of colorectal adenocarcinoma;\". Sites: Italy. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06640166","url":"https://clinicaltrials.gov/study/NCT06640166"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["colon-cancer","braf-v600e-colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["pierre-fabre"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06640166","phase":"2","setting":"Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","enrolled":25,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06640166/","neighbours":{"cancer":[{"id":"braf-v600e-colorectal","kind":"cancer","name":"BRAF V600E-mutant colorectal cancer","route":"/cancers/braf-v600e-colorectal/"},{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"}],"company":[{"id":"pierre-fabre","kind":"company","name":"Pierre Fabre","route":"/companies/pierre-fabre/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}